Evidence WG

Primær information

  • Handelsnavn:
  • Evidence WG Pulver
  • Lægemiddelform:
  • Pulver
  • Sammensætning:
  • 400 g/kg pirimicarb; 20 g/kg deltamethrin
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Evidence WG Pulver
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Udgået
  • Sidste ændring:
  • 08-02-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

28-3-2018

DKMA Update March 2018

DKMA Update March 2018

In this issue of DKMA Update you can read about evidence; changes to Tramadol’s summary of product characteristics; inspections of the sale of OTC medicines outside pharmacies and much more

Danish Medicines Agency

5-3-2018

FDA Drug Safety Communication: FDA review found no increased cardiovascular risks with Parkinson’s disease drug entacapone

FDA Drug Safety Communication: FDA review found no increased cardiovascular risks with Parkinson’s disease drug entacapone

[10-26-2015] A Food and Drug Administration (FDA) safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease.

FDA - U.S. Food and Drug Administration

6-2-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse

FDA statement on scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse

FDA - U.S. Food and Drug Administration

2-2-2018

Statement from Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health on the recent National Toxicology Program draft report on radiofrequency energy exposure

Statement from Jeffrey Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health on the recent National Toxicology Program draft report on radiofrequency energy exposure

One part of the Food and Drug Administration’s mission is to ensure the safety of electronic products that emit radiation, like televisions and cell phones. These types of products are part of Americans’ daily life and we take our duty to protect consumers with the utmost gravity. With cell phones, we have relied extensively on a myriad scientific evidence developed over many years to help inform our regulatory thinking. Although the Federal Communications Commission (FCC) sets the standard for radiofreq...

FDA - U.S. Food and Drug Administration

22-12-2017

Unauthorized Ultra Pure Colloidal Silver Product May Pose Serious Health Risk

Unauthorized Ultra Pure Colloidal Silver Product May Pose Serious Health Risk

Health Canada is advising Canadians, especially children and pregnant women, not to use the unauthorized product Ultra Pure Colloidal Silver by ECG Naturals because it may pose a serious risk to health. Consumers taking this product are at risk of developing a condition called generalized argyria, which is the permanent bluish-gray discolouration of the skin, eyes and nails. At this time, there is no scientific evidence that supports the use of colloidal silver for any specific disease or condition in hu...

Health Canada

11-12-2017

FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required

FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required

[6-24-2014] The U.S. Food and Drug Administration (FDA) has completed its safety review and has found no clear evidence of increased cardiovascular risks associated with use of the blood pressure medication olmesartan in diabetic patients.

FDA - U.S. Food and Drug Administration

21-6-2017

 Evaluation of a Danish meta-analysis of antidepressants

Evaluation of a Danish meta-analysis of antidepressants

The Danish Medicines Agency has evaluated a Danish meta-analysis made by the Copenhagen Trial Unit on the effects of antidepressants (SSRIs). The analysis attracted extensive media coverage. In connection with a consultation of the Danish Parliament’s Health and Senior Citizen's Committee, the Danish Medicines Agency has made a thorough evaluation of a Danish meta-analysis of antidepressants prepared by the Copenhagen Trial Unit (CTU). The CTU’s meta-analysis attracted considerable media coverage earlie...

Danish Medicines Agency

23-5-2017

FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue

FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue

An FDA review to date has not identified adverse health effects from gadolinium retained in the brain after the use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI). All GBCAs may be associated with some gadolinium retention in the brain and other body tissues. However, because we identified no evidence to date that gadolinium retention in the brain from any of the GBCAs, including GBCAs associated with higher retention of gadolinium, is harmful, restricting GBCA use is ...

FDA - U.S. Food and Drug Administration

17-5-2017

FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis

FDA expands approved use of Kalydeco to treat additional mutations of cystic fibrosis

The U.S. Food and Drug Administration today expanded the approved use of Kalydeco (ivacaftor) for treating cystic fibrosis. The approval triples the number of rare gene mutations that the drug can now treat, expanding the indication from the treatment of 10 mutations, to 33. The agency based its decision, in part, on the results of laboratory testing, which it used in conjunction with evidence from earlier human clinical trials. The approach provides a pathway for adding additional, rare mutations of the...

FDA - U.S. Food and Drug Administration

29-3-2018

Katie also works with stakeholders to improve diverse clinical study participation and resulting scientific evidence to reduce healthcare disparities
#WomensHistoryMonthpic.twitter.com/N1wQJ5h0Ab

Katie also works with stakeholders to improve diverse clinical study participation and resulting scientific evidence to reduce healthcare disparities #WomensHistoryMonthpic.twitter.com/N1wQJ5h0Ab

Katie also works with stakeholders to improve diverse clinical study participation and resulting scientific evidence to reduce healthcare disparities #WomensHistoryMonth pic.twitter.com/N1wQJ5h0Ab

FDA - U.S. Food and Drug Administration

29-3-2018

She focuses on directing the Center’s patient engagement as well as initiatives to advance the science and adoption of patient input as evidence, including Patient Preference Information and Patient Reported Outcomes... #WomensHistoryMonth

She focuses on directing the Center’s patient engagement as well as initiatives to advance the science and adoption of patient input as evidence, including Patient Preference Information and Patient Reported Outcomes... #WomensHistoryMonth

She focuses on directing the Center’s patient engagement as well as initiatives to advance the science and adoption of patient input as evidence, including Patient Preference Information and Patient Reported Outcomes... #WomensHistoryMonth

FDA - U.S. Food and Drug Administration

29-3-2018

CEFEPIME Injection, Powder, For Solution [WG Critical Care, LLC]

CEFEPIME Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Mar 29, 2018 EST

US - DailyMed

23-3-2018

ESMOLOL HYDROCHLORIDE Injection [WG Critical Care, LLC]

ESMOLOL HYDROCHLORIDE Injection [WG Critical Care, LLC]

Updated Date: Mar 23, 2018 EST

US - DailyMed

7-3-2018

News and press releases:  EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta

News and press releases: EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta

Evidence indicates risk of serious inflammatory brain disorders

Europe - EMA - European Medicines Agency

11-1-2018

Hawthorn

Hawthorn

Hawthorn suggested uses include for arrhythmias, atherosclerosis, Buerger's disease, circulatory disorders, congestive heart failure (CHF), hyperlipidemia, high blood pressure (hypertension), low blood pressure (hypotension), indigestion, and tapeworm infections. There is contradictory evidence about the effects of hawthorn extract in heart failure patients.

US - RxList

10-1-2018

MAGNESIUM SULFATE Injection [WG Critical Care, LLC]

MAGNESIUM SULFATE Injection [WG Critical Care, LLC]

Updated Date: Jan 10, 2018 EST

US - DailyMed

8-1-2018

5% DEXTROSE Injection, Solution [WG Critical Care, LLC]

5% DEXTROSE Injection, Solution [WG Critical Care, LLC]

Updated Date: Jan 8, 2018 EST

US - DailyMed

5-1-2018

0.9% SODIUM CHLORIDE Injection, Solution [WG Critical Care, LLC]

0.9% SODIUM CHLORIDE Injection, Solution [WG Critical Care, LLC]

Updated Date: Jan 5, 2018 EST

US - DailyMed

3-1-2018

PLASMA-LYTE Injection, Solution [WG Critical Care, LLC]

PLASMA-LYTE Injection, Solution [WG Critical Care, LLC]

Updated Date: Jan 3, 2018 EST

US - DailyMed

7-12-2017

QUARTERMASTER (Penicillin In Dihydrostreptomycin) Suspension [WG Critical Care, LLC]

QUARTERMASTER (Penicillin In Dihydrostreptomycin) Suspension [WG Critical Care, LLC]

Updated Date: Dec 7, 2017 EST

US - DailyMed

28-11-2017

Hospitals Vary Widely in Management of Infant Bronchiolitis

Hospitals Vary Widely in Management of Infant Bronchiolitis

Among infants hospitalized with bronchiolitis, use of evidence-based supportive therapies (EBST) varies widely across hospitals, a new study shows.

US - RxList

28-11-2017

Physical Activity Reduces Cardiovascular Risk

Physical Activity Reduces Cardiovascular Risk

More Evidence Physical Activity Reduces Cardiovascular Risk

US - eMedicineHealth

28-11-2017

AMPICILLIN Injection, Powder, For Solution [WG Critical Care, LLC]

AMPICILLIN Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Nov 28, 2017 EST

US - DailyMed

13-11-2017

Exercise Linked to Improved Brain Connectivity in MS

Exercise Linked to Improved Brain Connectivity in MS

PARIS — Further evidence that exercise may play a positive role in multiple sclerosis (MS) has come from a novel study of brain network connectivity.

US - RxList

13-11-2017

Presentation: Clinical evidence and access for medicinal cannabis products

Presentation: Clinical evidence and access for medicinal cannabis products

Overview of clinical evidence and access for medicinal cannabis products

Therapeutic Goods Administration - Australia

10-11-2017

TGA presentation: RACGP (GP17) conference, 26-28 October 2017

TGA presentation: RACGP (GP17) conference, 26-28 October 2017

Overview of clinical evidence and access for medicinal cannabis products

Therapeutic Goods Administration - Australia

27-10-2017

CEFTRIAXONE Injection, Powder, For Solution [WG Critical Care, LLC]

CEFTRIAXONE Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Oct 27, 2017 EST

US - DailyMed

27-10-2017

CEFAZOLIN Injection, Powder, For Solution [WG Critical Care, LLC]

CEFAZOLIN Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Oct 27, 2017 EST

US - DailyMed

26-10-2017

CEFTAZIDIME Injection, Powder, For Solution [WG Critical Care, LLC]

CEFTAZIDIME Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Oct 26, 2017 EST

US - DailyMed

23-10-2017

More Evidence That Depression Shortens Lives

More Evidence That Depression Shortens Lives

Title: More Evidence That Depression Shortens LivesCategory: Health NewsCreated: 10/23/2017 12:00:00 AMLast Editorial Review: 10/23/2017 12:00:00 AM

US - MedicineNet

18-10-2017

10/10 CDRH Real World Evidence Webinar materials and survey now available  https://go.usa.gov/xnrY6  and survey http://ow.ly/S7TV30fXyo6 

10/10 CDRH Real World Evidence Webinar materials and survey now available https://go.usa.gov/xnrY6  and survey http://ow.ly/S7TV30fXyo6 

10/10 CDRH Real World Evidence Webinar materials and survey now available https://go.usa.gov/xnrY6  and survey http://ow.ly/S7TV30fXyo6 

FDA - U.S. Food and Drug Administration

17-10-2017

NAFCILLIN Powder, For Solution [WG Critical Care, LLC]

NAFCILLIN Powder, For Solution [WG Critical Care, LLC]

Updated Date: Oct 17, 2017 EST

US - DailyMed

3-10-2017

Pain - randomised controlled trials and other studies

Pain - randomised controlled trials and other studies

Bibliography of major studies used in developing reviews of clinical evidence for medicinal cannabis and cannabis products

Therapeutic Goods Administration - Australia

3-10-2017

Palliation - randomised controlled trials and other studies

Palliation - randomised controlled trials and other studies

Bibliography of major studies used in developing reviews of clinical evidence for medicinal cannabis and cannabis products

Therapeutic Goods Administration - Australia

15-9-2017

News and press releases:  Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes

News and press releases: Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes

EMA concludes review of human factor VIII medicines authorised in EU

Europe - EMA - European Medicines Agency

30-8-2017

Real-World Evidence to Support Regulatory Decision-Making for Devices.  https://go.usa.gov/xRAEd  #MedicalDevice #NEST #realworlddata #data

Real-World Evidence to Support Regulatory Decision-Making for Devices. https://go.usa.gov/xRAEd  #MedicalDevice #NEST #realworlddata #data

Real-World Evidence to Support Regulatory Decision-Making for Devices. https://go.usa.gov/xRAEd  #MedicalDevice #NEST #realworlddata #data

FDA - U.S. Food and Drug Administration

29-8-2017

Access to medicinal cannabis products

Access to medicinal cannabis products

New information on review of clinical evidence for medicinal cannabis and cannabis products

Therapeutic Goods Administration - Australia

29-8-2017

Epilepsy - randomised controlled trials and other studies

Epilepsy - randomised controlled trials and other studies

Bibliography of major studies used in developing reviews of clinical evidence for medicinal cannabis and cannabis products

Therapeutic Goods Administration - Australia

29-8-2017

Multiple sclerosis - randomised controlled trials and other studies

Multiple sclerosis - randomised controlled trials and other studies

Bibliography of major studies used in developing reviews of clinical evidence for medicinal cannabis and cannabis products

Therapeutic Goods Administration - Australia

29-8-2017

Nausea and vomiting - randomised controlled trials and other studies

Nausea and vomiting - randomised controlled trials and other studies

Bibliography of major studies used in developing reviews of clinical evidence for medicinal cannabis and cannabis products

Therapeutic Goods Administration - Australia

11-8-2017

Prehypertension in Midlife Ups Later Dementia Risk

Prehypertension in Midlife Ups Later Dementia Risk

A new study provides more evidence that midlife vascular risk factors, such as hypertension, diabetes, and smoking, increase the risk for dementia in later life — and adds new data showing that prehypertension is also an important risk factor. The study also suggests that the association between diabetes and dementia is "much larger than we expected; the risk associated with midlife diabetes is almost as high as the risk associated with having an e4 copy of the APOE gene, which is the strongest known gen...

US - RxList

8-8-2017

Bone Up on Prostate Cancer Treated With ADT

Bone Up on Prostate Cancer Treated With ADT

Bone health drugs are effective in improving bone mineral density (BMD) in patients with nonmetastatic prostate cancer who receive androgen deprivation therapy (ADT), but there is little or no evidence that they prevent fractures, according to a new systematic review and meta-analysis.

US - RxList

27-7-2017

News and press releases:  EU report: more evidence on link between antibiotic use and antibiotic resistance

News and press releases: EU report: more evidence on link between antibiotic use and antibiotic resistance

The European Food Safety Authority, the European Medicines Agency and the European Centre for Disease Prevention and Control are concerned about the impact of use of antibiotics on the increase in antibiotic-resistant bacteria.

Europe - EMA - European Medicines Agency

20-7-2017

PENICILLIN G POTASSIUM Injection, Powder, For Solution [WG Critical Care, LLC]

PENICILLIN G POTASSIUM Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Jul 20, 2017 EST

US - DailyMed

11-7-2017

CEFOXITIN Injection, Powder, For Solution [WG Critical Care, LLC]

CEFOXITIN Injection, Powder, For Solution [WG Critical Care, LLC]

Updated Date: Jul 11, 2017 EST

US - DailyMed

21-6-2017

LEVOFLOXACIN Injection, Solution [WG Critical Care, LLC]

LEVOFLOXACIN Injection, Solution [WG Critical Care, LLC]

Updated Date: Jun 21, 2017 EST

US - DailyMed

9-6-2017

News and press releases:  PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel

News and press releases: PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel

Doctors advised to follow recommendations in current product information

Europe - EMA - European Medicines Agency

24-5-2017

New Drug Eases Chronic Cough

New Drug Eases Chronic Cough

Refractory chronic cough can be relieved with a P2X3 inhibitor, evidence from a phase 2b clinical trial shows.

US - RxList

27-4-2017

Cheap Drug Cuts Maternal Deaths Due to Postpartum Hemorrhage

Cheap Drug Cuts Maternal Deaths Due to Postpartum Hemorrhage

Among women with postpartum hemorrhage, administration of tranexamic acid significantly reduces death due to bleeding, with no evidence of any adverse effects, results of a randomized controlled trial show.

US - RxList